Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Shares Outstanding (Weighted Average) (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Shares Outstanding (Weighted Average) for 11 consecutive years, with $108.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 9.64% to $108.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $108.4 million, a 9.64% increase, with the full-year FY2025 number at $108.4 million, up 9.64% from a year prior.
  • Shares Outstanding (Weighted Average) was $108.4 million for Q4 2025 at Intellia Therapeutics, down from $110.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $110.2 million in Q3 2025 to a low of $67.2 million in Q1 2021.
  • A 5-year average of $87.5 million and a median of $88.3 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 35.94% in 2021, then rose 3.18% in 2022.
  • Intellia Therapeutics' Shares Outstanding (Weighted Average) stood at $70.9 million in 2021, then rose by 8.57% to $77.0 million in 2022, then grew by 15.33% to $88.8 million in 2023, then increased by 11.35% to $98.8 million in 2024, then increased by 9.64% to $108.4 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Shares Outstanding (Weighted Average) are $108.4 million (Q4 2025), $110.2 million (Q3 2025), and $103.6 million (Q2 2025).